Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 9:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sars-CoV2 Clear all
Completed No phase listed Observational

Yale COVID-19 Recovery Study

NCT04895189
View directory record Official record
Conditions
Covid19 Sequelae
Interventions
No intervention
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 26, 2026, 9:54 AM EDT
Withdrawn Phase 3 Interventional

Outpatient Use of Ivermectin in COVID-19

NCT04530474
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin Pill, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 26, 2026, 9:54 AM EDT
Completed Phase 4 Interventional

COVID-19 VaccinE Response in Rheumatology Patients

NCT05080218
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions
Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
Drug
Lead sponsor
Jeffrey Curtis
Other
Eligibility
18 Years to 85 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 26, 2026, 9:54 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Antiviral Efficacy and Acceptability of Mouth Rinses for Inactivation of COVID-19

NCT04748783
View directory record Official record
Conditions
COVID19, Coronavirus Infection, SARS CoV-2 Infection
Interventions
Water, Peroxyl, Periogard, Colgate Total Zero
Other · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 26, 2026, 9:54 AM EDT
Completed No phase listed Observational

Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)

NCT04350073
View directory record Official record
Conditions
COVID-19
Interventions
Q-NRG Metobolic Cart Device, MuscleSound Ultrasound, Multifrequency Bioimpedance Spectroscopy
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 26, 2026, 9:54 AM EDT
Completed Phase 3 Interventional

ACTIV-3: Therapeutics for Inpatients With COVID-19

NCT04501978
View directory record Official record
Conditions
Covid19
Interventions
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
98
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 26, 2026, 9:54 AM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19

NCT04358068
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Hydroxychloroquine (HCQ), Azithromycin (Azithro), Placebo for Hydroxychloroquine, Placebo for Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 26, 2026, 9:54 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

NCT05487040
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332 (nirmatrelvir)/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
52
States / cities
Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 26, 2026, 9:54 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm

NCT04362137
View directory record Official record
Conditions
Cytokine Storm (Covid-19)
Interventions
Ruxolitinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
11
States / cities
Fullerton, California • Aurora, Colorado • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 26, 2026, 9:54 AM EDT
Not listed No phase listed Observational

Long COVID-19 and MAB Study

NCT05508295
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
MultiCare Health System Research Institute
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 26, 2026, 9:54 AM EDT
Completed No phase listed Observational Results available

The Impact of Vaccination on Severity of Illness in COVID-19

NCT04912700
View directory record Official record
Conditions
Covid19
Interventions
COVID-19 vaccine
Biological
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
11,834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 26, 2026, 9:54 AM EDT
Completed Phase 2 Interventional Results available

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection

NCT04357730
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome
Interventions
Alteplase 50 MG [Activase]
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
La Jolla, California • Aurora, Colorado • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 26, 2026, 9:54 AM EDT
Active, not recruiting No phase listed Observational

Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans

NCT04565067
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years to 100 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 9:54 AM EDT
Active, not recruiting Not applicable Interventional

A Multimodal Parent-focused Intervention for Vulnerable Populations in the Bronx

NCT04991467
View directory record Official record
Conditions
Parenting, Covid19
Interventions
CARE Program and Valera Application with care manager functionality, Valera Application with care manager functionality, CARE Program, Valera Application, CARE Program and Valera Application
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 26, 2026, 9:54 AM EDT
Withdrawn Phase 2 Interventional

Coronavirus Smell Therapy for Anosmia Recovery

NCT04422275
View directory record Official record
Conditions
Anosmia
Interventions
Budesonide, High-Concentration Essential Oil, Placebo, Low-Concentration Essential Oil
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 26, 2026, 9:54 AM EDT
Completed No phase listed Observational

Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)

NCT04383730
View directory record Official record
Conditions
Critically Illness, Sedation, Invasive Mechanical Ventilation, Acute Respiratory Distress Syndrome
Interventions
Intravenous sedation, Inhaled sedation
Drug
Lead sponsor
University Hospital, Clermont-Ferrand
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 26, 2026, 9:54 AM EDT
Terminated Phase 3 Interventional Results available

VA CoronavirUs Research and Efficacy Studies-1

NCT04539275
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent Plasma, Masked Saline Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 26, 2026, 9:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)

NCT04345601
View directory record Official record
Conditions
Sars-CoV2, Acute Respiratory Distress Syndrome, COVID-19
Interventions
Mesenchymal Stromal Cells, Supportive Care
Biological · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 26, 2026, 9:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

NCT04402060
View directory record Official record
Conditions
COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome
Interventions
APL-9, Vehicle Control
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 26, 2026, 9:54 AM EDT
Completed Phase 3 Interventional Results available

CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION

NCT04333732
View directory record Official record
Conditions
COVID 19
Interventions
MR or M-M-R II ® vaccine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
3,411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 26, 2026, 9:54 AM EDT
Completed No phase listed Observational

Do EEG and Neurocognitive Assessments Correlate With COVID Brainfog Symptoms?

NCT05303116
View directory record Official record
Conditions
COVID-19
Interventions
Brainscope modified EEG and cognitive testing
Diagnostic Test
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 26, 2026, 9:54 AM EDT
Completed No phase listed Observational

Pediatric Acute Kidney Injury in COVID-19

NCT04466306
View directory record Official record
Conditions
Acute Kidney Injury, COVID
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
7 Days to 25 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
33
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 26, 2026, 9:54 AM EDT
Completed Phase 3 Interventional Results available

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729606
View directory record Official record
Conditions
Covid19
Interventions
Aviptadil, Aviptadil Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 26, 2026, 9:54 AM EDT